Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 1/2
3(60.0%)
Phase 1
1(20.0%)
Phase 2
1(20.0%)
5Total
Phase 1/2(3)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00504998Phase 1/2Completed

Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer

Role: lead

NCT00505271Phase 1/2Completed

Safety and Efficacy Study Using Rexin-G for Breast Cancer

Role: lead

NCT00505713Phase 1/2Completed

Safety and Efficacy Study Using Rexin-G for Sarcoma

Role: lead

NCT00572130Phase 2Completed

Phase II Study of Intravenous Rexin-G in Osteosarcoma

Role: lead

NCT00121745Phase 1Terminated

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Role: lead

All 5 trials loaded